The post FET Technical Analysis Feb 10 appeared on BitcoinEthereumNews.com. FET price is currently stuck at the 0.16$ level and testing the critical support zoneThe post FET Technical Analysis Feb 10 appeared on BitcoinEthereumNews.com. FET price is currently stuck at the 0.16$ level and testing the critical support zone

FET Technical Analysis Feb 10

FET price is currently stuck at the 0.16$ level and testing the critical support zone at 0.1558$; while the downward trend continues, RSI at 30.82 gives an oversold signal, but staying below resistance at 0.1611$ could trigger a decline.

Current Price Position and Critical Levels

FET, with its current price at 0.16$ following a 24-hour 2.23% decline, is positioned within the overall downtrend. The price is trading below EMA20 (0.19$), giving short-term bearish signals, and the Supertrend indicator is pointing to 0.21$ resistance. Across multiple timeframes (1D/3D/1W), 8 strong levels have been identified: 2 supports/1 resistance on 1D, 2 supports/1 resistance on 3D, and 1 support/2 resistance confluence on 1W. These levels are strengthened by past tests, volume increases, and liquidity accumulation zones. The current price position shows consolidation near the 0.1558$ support zone; without an upward breakout from here, deeper corrections may come into play.

Support Levels: Buyer Zones

Primary Support

The primary support level at 0.1558$ (score: 66/100) stands out as the nearest buyer zone. This level coincides with the order block of the last downward wave on the 1D timeframe and has been tested 3 times in the past, producing strong bounces. Volume data shows buyers entering in this zone; for example, volume spikes were observed in the last week’s candle closes. Multi-timeframe confluence is high: it overlaps with the demand zone on the 3D chart and aligns with the Fibonacci 0.618 retracement on 1W. As price approaches here, combined with oversold RSI (30.82), it carries V-shaped recovery potential. The importance of this level lies in the liquidity pool gathered here; large players can sweep stop-losses and create upward manipulation.

Secondary Support and Stop Levels

Secondary support at 0.1340$ (score: 75/100) is critical as a deeper buyer zone and invalidation point. This level is at the confluence of the main demand zone on 1W and the breaker block on 3D; historically, it has shown an 80% success rate over 4 tests. The volume profile contains high volume nodes (HVN) in this zone, meaning institutional buying is concentrated here. It gains extra strength by overlapping with EMA50 (around 0.14$). The invalidation level activates on a break below 0.1340$; in that case, the downside target could extend to 0.0453$ (score 22/100), which aligns with the 1W swing low. Traders should place stop-loss for long positions at 0.1330$, achieving a risk/reward ratio of 1:3.

Resistance Levels: Seller Zones

Near-Term Resistances

Near-term resistance at 0.1611$ (score: 66/100) is the first seller zone the price will test. This level is defined by the last high-volume rejection wick on 1D and serves as the first obstacle approaching EMA20 (0.19$). There have been 2 failed breakout attempts in the past, accompanied by volume decline. It coincides with supply imbalance on the 3D chart, making it an ideal point for liquidity grabs. If price fails to break this, short-term bearish continuation is expected.

Main Resistance and Targets

Main resistances are concentrated between 0.19$ (EMA20) and 0.21$ (Supertrend); there is a 2 strong resistance confluence on 1W. The 0.2971$ upside target (score 26/100) is at the intersection of Fibonacci extension 1.618 and the 3D trendline. These levels have been tested with historically high-volume sales; for example, 0.21$ is the equal highs zone of the last rally. Volume increase is required for a breakout; otherwise, fakeout risk is high. Reaching major targets depends on BTC correlation.

Liquidity Map and Large Players

The liquidity map shows stop-hunting potential below 0.1558$; large players (smart money) can collect retail stops in this zone and create an upward impulse. Above, there is a sell-side liquidity pool between 0.1611$-0.19$, offering short squeeze opportunities. Order blocks are mapped as bullish OB at 0.1340$ and bearish OB at 0.21$. According to the volume profile, price is in a low volume node (LVN) around 0.16$, open to quick moves. With dominance effects, a BTC decline could accelerate liquidity sweeps in FET. Overall outlook: In the downtrend, buyers must defend 0.1558$, otherwise a test of 0.1340$ is inevitable.

Bitcoin Correlation

As a highly correlated altcoin with BTC ($69,209, 1.74% decline), FET is directly affected by BTC’s downtrend. BTC supports at 68,343$, 62,910$, and 46,196$; without a bounce from here, FET downside to 0.1340$ accelerates. BTC resistances at 70,938$, 77,357$; while BTC Supertrend is bearish, FET rally remains limited. To watch: BTC break below 68,343$ opens doors to 0.13$ in FET, while above 70,938$ gives green light to 0.19$ for FET. For altcoin season, BTC dominance decline is required.

Trading Plan and Level-Based Strategy

Level-based outlook: Holding above 0.1558$ gives long bias (targets 0.1611$-0.19$, stop 0.1540$); below gives short (target 0.1340$, stop 0.1620$). Breakout scenarios: Above 0.1611$ bullish continuation to 0.2971$, below 0.1340$ bearish to 0.0453$. R/R ratio around 1:4 upside, 1:2 downside. For spot, check FET Spot Analysis; for futures, FET Futures Analysis. This is market opinion and not investment advice; always prioritize risk management.

This analysis uses Chief Analyst Devrim Cacal’s market views and methodology.

Strategy Analyst: David Kim

Macro market analysis and portfolio management

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/fet-technical-analysis-february-10-2026-support-and-resistance-levels

Market Opportunity
FET Logo
FET Price(FET)
$0.1564
$0.1564$0.1564
-2.43%
USD
FET (FET) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26